CN1385151A - Slow-released dosage form of sodium ferulate and preparation process thereof - Google Patents
Slow-released dosage form of sodium ferulate and preparation process thereof Download PDFInfo
- Publication number
- CN1385151A CN1385151A CN 02111691 CN02111691A CN1385151A CN 1385151 A CN1385151 A CN 1385151A CN 02111691 CN02111691 CN 02111691 CN 02111691 A CN02111691 A CN 02111691A CN 1385151 A CN1385151 A CN 1385151A
- Authority
- CN
- China
- Prior art keywords
- sodium ferulate
- slow
- compritol
- ato
- ferulate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention uses hydroxypropyl methylcellulose or glycerol behenate as slow-seleased auxiliary material, and adopts tableting process and solid dispersion technique to make sodium ferulate into various slow-released dosage forms whose slow-releasing effect can be up to 12-24 hr, so as to reduce frequency of administration and make blood medicine concentration retain smoothly and stably in longer time.
Description
Technical field:
The present invention relates to medical technical field, is slow release formulation of sodium ferulate and preparation method thereof.
Background technology:
Sodium ferulate is the water-soluble active ingredient that extracts from Radix Angelicae Sinensis or Rhizoma Chuanxiong, claim angelicin or Rhizoma Chuanxiong element again, chemistry 3-methoxyl group 4 hydroxyls by name-phenylpropyl alcohol diluted acid sodium are the common drugs of treatment cardiovascular and cerebrovascular disease, and its pharmaceutical dosage form has regular dosage forms such as conventional tablet, powder and aqueous pharmaceutical.Because the sodium ferulate biological half-life is short, oral post-absorption is fast, therefore elimination in vivo is also fast, for keeping steady blood drug level, must increase administration number of times, usually take 3～4 times every day, thereby bring inconvenience, and how medicining times often causes the drug level big defective of undulatory property in vivo to the patient especially patient of long-term prescription.
Summary of the invention:
The present invention makes slow release formulation as insoluble skeleton with sodium ferulate as the hydrophilic gel skeleton or with Tridocosanoin (Compritol888 ATO) with hypromellose (HPMC), thereby reduced administration number of times, blood drug level is kept steadily in a long time, not only overcome drug level that multiple dosing brings undulatory property big defective in vivo, also provide convenience for the patient.HPMC is the propylene glycol high molecular polymer of methylcellulose, and after water or physiological fluid contacted, its polymer chain stretched, and volumetric expansion makes drug slow release in the system, so HPMC has been widely used in the preparation of oral drugs slow releasing preparation.Compritol 888 ATO are got by glycerol and behenateization, and the medicinal slow-release auxiliary material for French Jia Fasai company produces also has been used to prepare the oral drugs slow releasing preparation.
Description of drawings:
Fig. 1 is the HPMC slow releasing tablet drug release-time graph of sodium ferulate.
Fig. 2 is the Compritol 888 ATO slow releasing tablet drug release-time graphs of sodium ferulate.
Fig. 3 is the drug release-time graph with the sodium ferulate Compritol 888 ATO slow releasing tablets of solid dispersion technology preparation.
Fig. 4 is the drug release-time graph with the sodium ferulate Compritol 888 ATO slow releasing capsulees of solid dispersion technology preparation.
The specific embodiment:
The preparation of embodiment 1 sodium ferulate HPMC slow releasing tablet
Get HPMC (block happy Kanggong department product) 1.6kg, sodium ferulate (Hengda Pharmaceutical Factory, Chengdu product, down with) 1kg crosses 80 mesh sieves, mix homogeneously respectively.Make binding agent with 10% polyvinylpyrrolidone alcoholic solution 1000mL, granulate with 14 mesh sieves, 60 ℃ of oven dry add magnesium stearate lubricant 27g, behind the mixing, use the rotary tablet machine tabletting.Promptly get the HPMC slow releasing tablet of sodium ferulate, every contains sodium ferulate 100mg.
The detection of slow release effect:
By " the commentaries on classics basket method of the Chinese pharmacopoeia relevant slow releasing preparation vitro drug release detection of version in 2000 is carried out.Get 6 of sodium ferulate HPMC slow releasing tablet, condition (37 ℃ of temperature in the analogue body, 50 rev/mins of rotating speeds), with 900mL water as release medium, measure the drug release situation by medicine intelligence dissolution test instrument (Radio Factory of Tianjin Univ.'s product), the results are shown in Figure 1, show that the HPMC slow releasing tablet of sodium ferulate has tangible slow release characteristic, the release of medicine can be kept 12 hours.Animal experiment is after 12 Canis familiaris L.s are taken medicine, and matched group sodium ferulate ordinary tablet (Hengda Pharmaceutical Factory, Chengdu product) promptly reaches the highest blood drug level taking medicine 5～15 minutes in, descends rapidly subsequently, and basic detection does not go out sodium ferulate in about 2 hours; And sodium ferulate HPMC slow releasing tablet, in the half an hour to 10 hour of taking medicine, all can keep effective blood drug concentration, and the fluctuation of drug level is little during rechallenge, illustrates that sodium ferulate HPMC slow releasing tablet has the good slow release characteristic, has reached 2 times the administration requirement of taking medicine every day.
The preparation of embodiment 2 sodium ferulate Compritol 888 ATO slow releasing tablets
Get Compritol 888 ATO (French Jia Fasai company product, down with) 1.5kg, sodium ferulate 1.5kg crosses 80 mesh sieves, mix homogeneously respectively.Make binding agent with 95% ethanol 200mL, granulate with 14 mesh sieves, 35 ℃ of oven dry add magnesium stearate 30g, behind the mixing, use the rotary tablet machine tabletting, promptly get sodium ferulate Compritol 888 ATO slow releasing tablets, and every contains sodium ferulate 150mg.
The detection of slow release effect:
Detection method the results are shown in Figure 2 with embodiment 1, shows that the Compritol 888 ATO slow releasing tablet of sodium ferulate have tangible slow release characteristic, and the release of medicine can be kept 12 hours.Carry out animal experiment with embodiment 1, sodium ferulate Compritol 888 ATO slow releasing tablet are taken Canis familiaris L. all can keep effective blood drug concentration to 10 and a half hours in back 20 minutes, the fluctuation of drug level is little during rechallenge, the Compritol 888 ATO slow releasing tablet that this sodium ferulate is described have good slow release characteristic, have reached 2 times the administration requirement of taking medicine every day.
Embodiment 3 solid dispersion technologies prepare sodium ferulate Compritol 888 ATO slow releasing tablet and capsules
Get Compritol 888 ATO1.5kg, after 80 ℃ of heating in water bath fusions, add sodium ferulate 1.5kg, constantly stir, make itself and the abundant mixing of Compritol 888 ATO, form solid dispersion, treat natural cooling after, pulverize with pulverizer (going up Haidian Chinese traditional medicine machine of a specified duration Manufacturing Co., Ltd product), crossing 30 mesh sieves, is binding agent with 95% ethanol 200mL then, is made into granule with 18 mesh sieves, 35 ℃ of oven dry are with its preparation slow releasing tablet or capsule.During the preparation tablet, add magnesium stearate 30g, behind the mixing, use the rotary tablet machine tabletting, promptly get the Compritol 888 ATO slow releasing tablets of sodium ferulate, every contains sodium ferulate 150mg.If the preparation capsule, the direct filling capsule of granule after then will drying as No. 1 hard capsule, promptly gets the Compritol 888 ATO slow releasing capsulees of sodium ferulate, and every capsules contains sodium ferulate 150mg.
The detection of slow release effect:
Detection method is with embodiment 1, the results are shown in Figure 3, Fig. 4, and Fig. 3 shows that sodium ferulate Compritol 888 ATO slow releasing tablet have tangible slow release characteristic, and the release of medicine can be kept 24 hours; Fig. 4 shows that the release of slow releasing capsule agent medicine also can keep 24 hours.Illustrate that this sodium ferulate slow releasing tablet and slow releasing capsule have all reached 1 time the administration requirement of taking medicine every day.
Claims (7)
1. the slow release formulation of sodium ferulate comprises medicine, binding agent, lubricant, it is characterized in that also comprising slow-release auxiliary material, and said medicine is a sodium ferulate, and binding agent is a polyvinylpyrrolidone, and lubricant is a magnesium stearate.
2. by the described sodium ferulate slow release formulation of claim 1, it is characterized in that said slow-release auxiliary material is hypromellose HPMC.
3. by the described sodium ferulate slow release formulation of claim 1, it is characterized in that said slow-release auxiliary material is Tridocosanoin Compritol 888 ATO.
4. the preparation method of the slow release formulation of the described sodium ferulate of claim 2, its component proportioning and operating procedure are as follows:
Sodium ferulate and HPMC are sieved behind the mixing in 1: 0.6～2.5 (W/W) ratio, add binding agent and granulate, oven dry adds lubricant mixing tabletting again, sodium ferulate HPMC slow releasing tablet.
5. the preparation method of the slow release formulation of the described sodium ferulate of claim 3, its component proportioning and operating procedure are as follows:
Sodium ferulate and Compritol 888 ATO are sieved behind the mixing in 1: 0.5～2.5 (W/W) ratio, add binding agent and granulate, oven dry adds lubricant mixing tabletting again, sodium ferulate Compritol 888 ATO slow releasing tablet.
6. the preparation method of the slow release formulation of the described sodium ferulate of claim 3, its component proportioning and operating procedure are as follows:
Get Compritol 888 ATO, after the heating in water bath fusion, be that 1: 0.2～2.0 (W/W) add sodium ferulate with the ratio of sodium ferulate and Compritol 888 ATO, constantly stir, make itself and the abundant mixing of Compritol 888 ATO, form solid dispersion, after cooling, crushing screening, adding binding agent granulates, oven dry adds lubricant mixing tabletting again, gets sodium ferulate Compritol 888 ATO slow releasing tablet.
7. the preparation method of the slow release formulation of the described sodium ferulate of claim 3, its component proportioning and operating procedure are as follows:
Get Compritol 888 ATO, after the heating in water bath fusion, be that 1: 0.2～2.0 (W/W) add sodium ferulate with the ratio of sodium ferulate and Compritol 888 ATO, constantly stir, make itself and the abundant mixing of Compritol 888 ATO, form solid dispersion, after cooling, crushing screening, adding binding agent granulates, oven dry then with the particle packing capsule, promptly gets sodium ferulate Compritol 888 ATO slow releasing capsulees.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02111691 CN1235576C (en) | 2002-05-16 | 2002-05-16 | Slow-released dosage form of sodium ferulate and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02111691 CN1235576C (en) | 2002-05-16 | 2002-05-16 | Slow-released dosage form of sodium ferulate and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1385151A true CN1385151A (en) | 2002-12-18 |
| CN1235576C CN1235576C (en) | 2006-01-11 |
Family
ID=4741690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02111691 Expired - Fee Related CN1235576C (en) | 2002-05-16 | 2002-05-16 | Slow-released dosage form of sodium ferulate and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1235576C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298318C (en) * | 2003-09-08 | 2007-02-07 | 天津太平洋制药有限公司 | Sodium ferulic acid osmosis pump controlled release formulation and its preparation method |
| CN1303990C (en) * | 2004-12-01 | 2007-03-14 | 北京科信必成医药科技发展有限公司 | Sodium ferulate oral disintegrating tablet and its preparation process |
| CN101278914B (en) * | 2008-01-02 | 2010-06-02 | 海南三叶美好制药有限公司 | Cefpodoxime proxetil suspension composition and preparation thereof |
| CN101103964B (en) * | 2006-07-14 | 2010-09-29 | 海南盛科生命科学研究院 | Sustained-release preparation containing felodipine and preparation method thereof |
| CN103830237A (en) * | 2014-03-21 | 2014-06-04 | 重庆康刻尔制药有限公司 | Isradipine composition medicine, capsule preparation, and preparation method and application of capsule preparation |
| CN106176684A (en) * | 2015-05-04 | 2016-12-07 | 深圳翰宇药业股份有限公司 | Sodium ferulate enteric slow releasing preparation and preparation method thereof |
-
2002
- 2002-05-16 CN CN 02111691 patent/CN1235576C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298318C (en) * | 2003-09-08 | 2007-02-07 | 天津太平洋制药有限公司 | Sodium ferulic acid osmosis pump controlled release formulation and its preparation method |
| CN1303990C (en) * | 2004-12-01 | 2007-03-14 | 北京科信必成医药科技发展有限公司 | Sodium ferulate oral disintegrating tablet and its preparation process |
| CN101103964B (en) * | 2006-07-14 | 2010-09-29 | 海南盛科生命科学研究院 | Sustained-release preparation containing felodipine and preparation method thereof |
| CN101278914B (en) * | 2008-01-02 | 2010-06-02 | 海南三叶美好制药有限公司 | Cefpodoxime proxetil suspension composition and preparation thereof |
| CN103830237A (en) * | 2014-03-21 | 2014-06-04 | 重庆康刻尔制药有限公司 | Isradipine composition medicine, capsule preparation, and preparation method and application of capsule preparation |
| CN103830237B (en) * | 2014-03-21 | 2016-06-29 | 重庆康刻尔制药有限公司 | A kind of isradipine composition of medicine, capsule, preparation method and application thereof |
| CN106176684A (en) * | 2015-05-04 | 2016-12-07 | 深圳翰宇药业股份有限公司 | Sodium ferulate enteric slow releasing preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1235576C (en) | 2006-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Devi et al. | Importance of novel drug delivery systems in herbal medicines | |
| CN104383123A (en) | Method for preparing golden camellia lipid-lowering blood sugar-reducing preparation | |
| KR20140016438A (en) | Ferric citrate dosage forms | |
| CN103845326A (en) | Compound composition of vildagliptin and melbine and preparation method thereof | |
| CN105934161A (en) | Composition of oily, pungent and odoriferous substances and process of preparation thereof | |
| CN1235576C (en) | Slow-released dosage form of sodium ferulate and preparation process thereof | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN1164264C (en) | Dispersed general arasaponin tablet and its prepn and application | |
| CN105560207A (en) | Naringin controlled release capsule and preparation method thereof | |
| JP2008526719A (en) | Method for producing sustained release controlled solid pharmaceutical composition by high pressure treatment | |
| CN109125270B (en) | Solid preparation and preparation method thereof | |
| CN102319225A (en) | Trimetazidine hydrochloride sustained release tablet and preparation method thereof | |
| CN102166241A (en) | Panax notoginseng saponins enteric microcapsule | |
| JP2000119190A (en) | Tablet containing chinese orthodox medicine and capsule filled with chinese orthodox medicine and tablet containing crude drug and capsule filled with crude drug, production of tablet containing chinese orthodox medicine, production of capsule filled with chinese orthodox medicine, production of tablet containing crude drug and production of capsule filled with crude drug mature | |
| DK2344140T3 (en) | Process for the preparation of bioadhesive compact matrices | |
| CN103371981A (en) | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof | |
| CN1709401A (en) | Chinese medicine slow-release formulation containing asiatic pennywort herb water-soluble active ingredient, and its preparing method | |
| CN102670545A (en) | Carvedilol push-pull osmotic pump type controlled release preparation and preparation method thereof | |
| CN101810593A (en) | Elemene sustained-release tablets | |
| JP2638604B2 (en) | Sustained release formulation | |
| KR102305932B1 (en) | Solid pharmaceutical composition of brown algae | |
| CN100358508C (en) | Delay, control release drug of prepared aconite root which can regulate the function of middle-warmer, and its preparation method | |
| CN100391454C (en) | Preparation of hydrobromic acid dextro methaphen and beta cyclodeatrin compounding object | |
| CN103099825A (en) | Novel cordyceps sinensis capsule and preparation method thereof | |
| CN101890057A (en) | Herba Pteridis Multifidae preparation that treatment gastrointestinal tract, urinary tract infection and the heart, cerebrovascular disease are used and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |